Re: Zenith got a licensing upgrade.
in response to
by
posted on
Nov 16, 2021 12:53PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
KOO - What you cited was only rentals and operating costs. There is also salaries and administration which in the past have usually been slightly larger so might be $400,000 for a total of $700,000. What I have copied below is from the April 30/21 annual financials. They usually put more detail in annuals. I have dealt with past reality rather than proposed future events but they don't seem to vary that much. This stated a net $700,000 in F2021 and $1 million in F2020 so yes, my $200,000 to $250,000 was quarterly.
"During the year ended April 30, 2021, Zenith incurred an aggregate of $0.7 million (2020 - $1.0 million) of service fees and reimbursable expenses, comprised of $0.4 million (2020 - $0.6 million) for management and administrative services provided by Resverlogix, and $0.4 million (2020 - $0.5 million) of reimbursable expenses, net of $0.1 million (2020 - $0.1 million) for services provided to Resverlogix by Zenith. The reimbursable expenses include proportionate share of rental payments and operating costs (for a laboratory and offices that Resverlogix shares with Zenith) pursuant to agreements that Resverlogix has in place with Zenith. As at April 30, 2021, Zenith owes Resverlogix $0.3 million (2020 - $0.9 million). This balance is unsecured, payable on demand and non-interest bearing. Effective January 1, 2015, Zenith entered into a Services Agreement with Resverlogix whereby Zenith supplies research services to Resverlogix. The purpose of the agreement is to enable Resverlogix to obtain access to specialized research services on a more cost-effective basis than other alternatives. During the year ended April 30, 2021, Zenith provided $0.02 million of research services (2020 - $0.1 million). As at April 30, 2021, Resverlogix owes Zenith $0.01 million related to work performed under the agreement (2020 - $0.1 million)."